Innovative Strategies for Drug Delivery to the Ocular Posterior Segment

Innovative and new drug delivery systems (DDSs) have recently been developed to vehicle treatments and drugs to the ocular posterior segment and the retina. New formulations and technological developments, such as nanotechnology, novel matrices, and non-traditional treatment strategies, open new per...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Gabai (Author), Marco Zeppieri (Author), Lucia Finocchio (Author), Carlo Salati (Author)
Format: Book
Published: MDPI AG, 2023-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9e478032c2904bccad6b961dd2d80933
042 |a dc 
100 1 0 |a Andrea Gabai  |e author 
700 1 0 |a Marco Zeppieri  |e author 
700 1 0 |a Lucia Finocchio  |e author 
700 1 0 |a Carlo Salati  |e author 
245 0 0 |a Innovative Strategies for Drug Delivery to the Ocular Posterior Segment 
260 |b MDPI AG,   |c 2023-07-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15071862 
500 |a 1999-4923 
520 |a Innovative and new drug delivery systems (DDSs) have recently been developed to vehicle treatments and drugs to the ocular posterior segment and the retina. New formulations and technological developments, such as nanotechnology, novel matrices, and non-traditional treatment strategies, open new perspectives in this field. The aim of this mini-review is to highlight promising strategies reported in the current literature based on innovative routes to overcome the anatomical and physiological barriers of the vitreoretinal structures. The paper also describes the challenges in finding appropriate and pertinent treatments that provide safety and efficacy and the problems related to patient compliance, acceptability, effectiveness, and sustained drug delivery. The clinical application of these experimental approaches can help pave the way for standardizing the use of DDSs in developing enhanced treatment strategies and personalized therapeutic options for ocular pathologies. 
546 |a EN 
690 |a drug delivery systems (DDSs) 
690 |a nanotechnology 
690 |a matrices 
690 |a ocular posterior segment 
690 |a vitreoretinal 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 7, p 1862 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/7/1862 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/9e478032c2904bccad6b961dd2d80933  |z Connect to this object online.